Blog Archive

Topline Phase IIb Data for AVI BioPharma’s Eteplirsen May Send the Stock Soaring

AVI BioPharma (AVII) is developing a treatment for Duchenne’s Muscular Dystrophy (DMD). A good overview of the disease and AVII’s clinical program was given in a presentation to a patient advocacy group. This article summarizes some of the key points from the presentation and looks at the investment potential of AVI BioPharma’s stock. Overview: Muscular

Biotech4cast Weekly Stock Digest March 25th

This upcoming week will be busy with three PDUFA dates and an advisory committee meeting, but first a look back. ARIAD (ARIA): On March 21, ODAC voted against approval of ARIAD’s ridaforolimus for the treatment of soft tissue/bone sarcomas. The outcome of this advisory committee meeting was expected and there were many calls to buy

Biotech4cast Stock Weekly Digest March 18th

This past week was a relatively quiet week for FDA meetings and decisions. ARIAD: On Friday the 16th of March the FDA released the briefing documents for the upcoming (March 20th) Oncologic Drugs Advisory Committee where ARIAD’s ridaforolimus for the treatment of soft tissue/bone sarcomas will be discussed. As a reminder, briefing documents provide insight

Trial Results for AVI BioPharma’s Eteplirsen Represents a Trading Catalyst.

AVI BioPharma is working on a treatment for Duchenne Muscular Dystrophy (DMD) called Eteplirsen. The disease is caused by a mutation in the dystrophin gene is which is important in muscle function. Eteplirsen is undergoing a phase IIb clinical trial to test if there is improvement in the dystrophin gene expression. On March 12, 2012

Biotech4cast Weekly Stock Digest March 11th

This week there were 2 rejections and 1 approval. The two rejections were expected, Astex Pharmaceuticals’ (ASTX) Dacogen for the treatment of Acute Myeloid Leukemia in the elderly and NeurogesX’s Qutenza 8% Patch for HIV-Associated peripheral neuropathy. Discovery Labs’ SURFAXIN for the prevention of Respiratory Distress Syndrome in premature infants was approved on March 6th.

Biotech4cast Weekly Stock Digest March 4th

Columbia Laboratories – No Approval for You! This week Columbia Laboratories (CBRX) received a complete response letter from the FDA and therefore will not be able to market their treatment for preterm birth in women with short uterine cervical length. This outcome was expected as the Biotech4cast Editor rating for Likelihood of success was 1/2 star